Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8071)
All Articles published online
|
Publishing Process of This Article
|
Dec 28, 2024 (publication date) through Feb 6, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Singh A, Sohal A, Batta A. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J Gastroenterol 2024; 30(48): 5205-5211 [PMID: 39735270 DOI: 10.3748/wjg.v30.i48.5205] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Singh A, Sohal A, Batta A. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J Gastroenterol 2024; 30(48): 5205-5211 [PMID: 39735270 DOI: 10.3748/wjg.v30.i48.5205] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v30/i48/5205.htm |
| Number | Citing Articles |
| 1 |
A. Pariente. Hepatopatías esteatósicas dismetabólicas. EMC - Tratado de Medicina 2025; 29(4): 1 doi: 10.1016/S1636-5410(25)51059-0
|
| 2 |
Yilmaz Gunes. A brief approach to hypertension in type 2 diabetes mellitus. Exploration of Endocrine and Metabolic Diseases 2025; doi: 10.37349/eemd.2025.101422
|
| 3 |
Junyu Wang, Jingting Lei, Martin C. Harmsen, Han Moshage. From cooperation to collapse: systemic failure in liver disease through a sociological lens. Exploration of Digestive Diseases 2025; 4 doi: 10.37349/edd.2025.100580
|
| 4 |
Ralf Weiskirchen. Resmetirom and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspective. Exploration of Drug Science 2025; 3 doi: 10.37349/eds.2025.1008132
|
| 5 |
Xinyi Zhang, Nanqin Peng, Xiaoyue Zhang, Zicheng Zhu, Yan Miao, Yuting Wu, Jitao Ling, Chen Li, Wenli Gu, Jing Zhang, Abudukeremu Ayiguli, Ziheng Zheng, Peng Yu, Xiao Liu. Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization. Diabetology & Metabolic Syndrome 2025; 17(1) doi: 10.1186/s13098-025-01712-w
|
| 6 |
A. Pariente. Hépatopathies stéatosiques dysmétaboliques. EMC - Traité de médecine AKOS 2025; 28(3): 1 doi: 10.1016/S1634-6939(25)49520-9
|
| 7 |
Surtika Tamilwanan, Zoriah Aziz, Lim Yan Rong, Ahmad Naoras Bitar, Raghdaa Hamdan Al Zarzour, Salah A. Alshehade. Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials. BMC Gastroenterology 2025; 25(1) doi: 10.1186/s12876-025-04358-0
|
| 8 |
Jiayi Chen, Shiyun Wu, Panpan Zhai, Xueting Ou, Liyang Zhou, Xingfei Pan. Global burden of hepatitis C virus infection related to high body mass index and future forecast: an analysis based on the global burden of disease study 2021. Frontiers in Public Health 2025; 13 doi: 10.3389/fpubh.2025.1685807
|
| 9 |
Joya Ghaleb, Katy Kaleen Khouzami, Nicolas Nassif, Philippe Attieh, Mohammad Feras Al Ajlani, Jana Bou Sleiman, Ali Khalouf, Frederic Harb, Sami Azar, Amjad Kanaan, Hilda E. Ghadieh, Suraiya Saleem. Unveiling Tirzepatide’s Therapeutic Spectrum: A Dual GIP/GLP‐1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health. International Journal of Endocrinology 2025; 2025(1) doi: 10.1155/ije/2876156
|
| 10 |
Arthur Anatolievich Lee, Victoria Alexandrovna Khotina, Dmitry Alexandrovich Kashirskikh, Olga Evgenevna Voronko, Vagif Ali oglu Gasanov, Andrey Valentinovich Vasiliev. Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact. Medical Sciences 2025; 13(4): 269 doi: 10.3390/medsci13040269
|
| 11 |
Angeliki Margoni, Kostas A. Papavassiliou, Athanasios G. Papavassiliou. Deliberating the striking effect of dual GLP-1R and GIPR agonists on “Diabesity” in light of precision medicine and pharmacogenomics. Metabolism Open 2025; 28: 100409 doi: 10.1016/j.metop.2025.100409
|
| 12 |
Fang Yao, Gaochao Wang, Fan Ning, Yanbo Shi. Targeting Ferroptosis: New Insights and Therapeutic Advances in MAFLD Complicating T2DM. Frontiers in Bioscience-Landmark 2025; 30(10) doi: 10.31083/FBL39735
|
| 13 |
Xing Wan, Jingyuan Ma, He Bai, Xuyang Hu, Yanna Ma, Mingjian Zhao, Jifeng Liu, Zhijun Duan. Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs. Biomolecules 2025; 15(1): 140 doi: 10.3390/biom15010140
|
| 14 |
Adam Vašura, Evžen Machytka, Marek Bužga, Jitka Macháčková, Jan Král. The significance of metabolism-associated steatotic liver disease and its treatment. Vnitřní lékařství 2025; 71(1): 29 doi: 10.36290/vnl.2025.005
|
| 15 |
Shujun Li, Nanqu Huang, Mei Wang, Wendi Huang, Yong Luo, Juan Huang. GLP-1R in diabetes mellitus: from basic discovery to therapeutics development. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1610512
|
| 16 |
Piotr Olejnik, Kaja Kasarełło, Renata Podkowińska-Polak, Aleksandra Golenia. Psoriasis: an emerging risk factor for ischemic stroke?. Frontiers in Neurology 2025; 16 doi: 10.3389/fneur.2025.1599978
|
| 17 |
Amirmohammad Abolhassani, Mohammed H. Moghadasian, Niloofar Sedaghatnezhad, Sadegh Jafarnejad. Anti-Dyslipidemic, Anti-Hypertensive, and Glycemic Control Effects of Akkermansia Muciniphila: Lesser-Known Benefits in Metabolic Syndrome – A Narrative Review. Heart and Mind 2025; 9(5): 398 doi: 10.4103/hm.HM-D-24-00161
|
| 18 |
Natalie Eppler, Elizabeth Jones, Forkan Ahamed, Yuxia Zhang. Multifaceted Human Antigen R (HuR): A Key Player in Liver Metabolism and MASLD. Livers 2025; 5(3): 33 doi: 10.3390/livers5030033
|
| 19 |
Anna Giannakogeorgou, Michael Roden, Kalliopi Pafili. Diabetes mellitus as a multisystem disease: understanding subtypes, complications, and the link with steatotic liver diseases in humans. Hormones 2025; doi: 10.1007/s42000-025-00701-y
|
| 20 |
Senping Xu, Zhaoshan Zhang, Zhongquan Zhou, Jiawei Guo. Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation. Biology 2026; 15(2): 148 doi: 10.3390/biology15020148
|
| 21 |
Iago Justo, María Calatayud, Javier Salamanca, María Camara, Alvaro García-Sesma, Carmelo Loinaz. Can we decrease the risk of complex liver surgery with the new GLP1 and GIP analogues?. Cirugía Española (English Edition) 2025; : 800264 doi: 10.1016/j.cireng.2025.800264
|
| 22 |
Krishna Bonga, Milan Padhan. Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control. Rambam Maimonides Medical Journal 2026; 17(1): e0006 doi: 10.5041/RMMJ.10565
|
| 23 |
Tariq Alrasheed, Mohamed E. A. Mostafa, Mohammed A Madkhali, Hesham A Khairy. Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis. Frontiers in Endocrinology 2026; 16 doi: 10.3389/fendo.2025.1734549
|
| 24 |
Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano. The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management. Exploration of Medicine 2025; 6 doi: 10.37349/emed.2025.1001365
|
| 25 |
Stefano Fiorucci, Ginevra Urbani. Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives. Expert Opinion on Investigational Drugs 2025; 34(9): 655 doi: 10.1080/13543784.2025.2546812
|
| 26 |
Pranav Patel. Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease. Journal of Clinical Medicine 2025; 14(17): 6060 doi: 10.3390/jcm14176060
|